Evaluation of Prostate-Specific Antigen (PSA) levels in patients with advanced prostate cancer treated with bicalutamide
Study identifier:NIS-OHR-CAS-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Non-interventional observational study to evaluate change of PSA levels in patients with advanced prostate cancer treated with bicalutamide in combination with medical or surgical castration
Medical condition
Advanced Prostate Cancer
Phase
-
Healthy volunteers
No
Study drug
-
Sex
Male
Actual Enrollment
340
Study type
Observational
Age
40 Years +
Date
Study Start Date: 01 Mar 2009
Primary Completion Date: 01 Jan 2010
Study Completion Date: 01 Jan 2010
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Ana Marija Gjurovic
AstraZeneca
